维罗纳制药 VRNA 深 沪
等待开盘 08-27 09:30:00 美东时间
106.91
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 106.91
- 总市值 919.33万
- 52周最高 106.93
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 31.60
- 委 比 0.00%
- 总股本 8.60万
- 历史最高 106.93
- 量 比 0
- 振 幅 0.00%
- 历史最低 2.01
- 每 手 1
- 风险率 0.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies
Fulcrum Therapeutics and Slate Medicines have agreed to merge in an all-stock transaction, with the combined company operating as Slate Medicines. The merger aims to advance Slate's pipeline of next-generation migraine therapeutics, including SLTE-1009, a clinical-stage anti-PACAP/VIP monoclonal antibody. Slate has secured $245 million in private placement financing, expected to fund operations into 2029. The transaction is subject to customary c...
08-17 11:00
Vor Bio Appoints David Zaccardelli to Board of Directors
Vor Bio appoints David Zaccardelli, Pharm.D., to its Board of Directors. With over 20 years of biopharmaceutical leadership experience, Dr. Zaccardelli has successfully navigated companies through late-stage development, regulatory approval, and commercial launch. His appointment comes as Vor Bio advances telitacicept, a novel dual-target fusion protein, through global Phase 3 trials for autoimmune diseases. Dr. Zaccardelli's leadership is expect...
07-07 20:01
Strong biopharma dealmaking market set to continue
The strong trend in pharma and biotech dealmaking, which has been ongoing for several years, should continue according to experts. Speaking at the FT US Pharma and Biotech Summit in New York, Eric Tok...
05-15 01:41
Achieve Life Sciences Reports Q1 2026 Results: Full Earnings Call Transcript
Achieve Life Sciences (NASDAQ:ACHV) held its first-quarter earnings conference ...
05-12 21:16
Merck Nears $6 Billion Deal To Buy Terns Pharma: Report
Merck is reportedly nearing a $6 billion acquisition of Terns Pharmaceuticals to strengthen its oncology pipeline ahead of Keytruda's patent expiry.
03-25 17:38
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
SAB Biotherapeutics reports progress on SAB-142's Phase 2b SAFEGUARD study for treating type 1 diabetes, with multiple patients dosed and enrollment on track to complete by end of 2026. Positive Phase 1 data highlight favorable safety profile and redosability. The company raised $175M in private placement to fully fund SAFEGUARD and has a strong cash position through 2028. Topline results expected in 2H2027.
03-09 21:16
